Resultats de la cerca - Fang‐Shu Ou
- Mostrar 1 - 20 resultats de 33
- Anar a la pàgina següent
-
1
-
2
-
3
-
4
Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance) per Kanwal Raghav, Fang‐Shu Ou, Alan P. Venook, Federico Innocenti, Ryan Sun, Heinz‐Josef Lenz, Scott Kopetz
Publicat 2022Artigo -
5
-
6
Clinical Significance of Post-Procedural TIMI Flow in Patients With Cardiogenic Shock Undergoing Primary Percutaneous Coronary Intervention per Rajendra H. Mehta, Fang‐Shu Ou, Eric D. Peterson, Richard E. Shaw, William B. Hillegass, John S. Rumsfeld, Matthew T. Roe
Publicat 2009Artigo -
7
-
8
Incidence and Prognostic Significance of Thrombocytopenia Developed During Acute Coronary Syndrome in Contemporary Clinical Practice per Tracy Y. Wang, Fang‐Shu Ou, Matthew T. Roe, Robert A. Harrington, E. Magnus Ohman, W. Brian Gibler, Eric D. Peterson
Publicat 2009Artigo -
9
The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in t... per Sripal Bangalore, F H Messerli, Fang‐Shu Ou, Jacqueline Tamis‐Holland, Angela Palazzo, M. T. Roe, Mun K. Hong, Eric D. Peterson
Publicat 2009Artigo -
10
Trends in the Association Between Age and In-Hospital Mortality After Percutaneous Coronary Intervention per Mandeep Singh, Eric D. Peterson, Matthew T. Roe, Fang‐Shu Ou, John A. Spertus, John S. Rumsfeld, H. Vernon Anderson, Lloyd W. Klein, Kalon K.L. Ho, David R. Holmes
Publicat 2009Artigo -
11
Impact of a Statewide ST-Segment–Elevation Myocardial Infarction Regionalization Program on Treatment Times for Women, Minorities, and the Elderly per Seth W. Glickman, Christopher B. Granger, Fang‐Shu Ou, Sean M. O’Brien, Barbara L. Lytle, Charles B. Cairns, Greg Mears, James W. Hoekstra, J. Lee Garvey, Eric D. Peterson, James G. Jollis
Publicat 2010Artigo -
12
Marine omega‐3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance) per Mingyang Song, Fang‐Shu Ou, Tyler Zemla, Mark A. Hull, Qian Shi, Paul J. Limburg, Steven R. Alberts, Frank A. Sinicrope, Edward L. Giovannucci, Erin L. Van Blarigan, Jeffrey A. Meyerhardt, Andrew T. Chan
Publicat 2019Artigo -
13
Percutaneous Coronary Interventions in Facilities Without Cardiac Surgery On Site: A Report From the National Cardiovascular Data Registry (NCDR) per Michael A. Kutcher, Lloyd W. Klein, Fang‐Shu Ou, Thomas P. Wharton, Gregory Dehmer, Mandeep Singh, H. Vernon Anderson, John S. Rumsfeld, William S. Weintraub, Richard E. Shaw, Matthew Sacrinty, Albert Woodward, Eric D. Peterson, Ralph G. Brindis
Publicat 2009Artigo -
14
Applying Recovery Biomarkers to Calibrate Self-Report Measures of Energy and Protein in the Hispanic Community Health Study/Study of Latinos per Yasmin Mossavar‐Rahmani, Pamela A. Shaw, William W. Wong, Daniela Sotres‐Alvarez, Marc D. Gellman, Linda Van Horn, Mark Stoutenberg, Martha L. Daviglus, Judith Wylie‐Rosett, Anna Maria Siega‐Riz, Fang‐Shu Ou, Ross L. Prentice
Publicat 2015Artigo -
15
Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance) per Heinz‐Josef Lenz, Fang‐Shu Ou, Alan P. Venook, Howard S. Höchster, Donna Niedzwiecki, Richard M. Goldberg, Robert J. Mayer, Monica M. Bertagnolli, Charles D. Blanke, Tyler Zemla, Xueping Qu, Pratyaksha Wirapati, Sabine Tejpar, Federico Innocenti, Omar Kabbarah
Publicat 2019Artigo -
16
Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome per Federico Innocenti, Fang‐Shu Ou, Xueping Qu, Tyler Zemla, Donna Niedzwiecki, Rachel Tam, Shilpi Mahajan, Richard M. Goldberg, Monica M. Bertagnolli, Charles D. Blanke, Hanna K. Sanoff, James N. Atkins, Blasé N. Polite, Alan P. Venook, Heinz‐Josef Lenz, Omar Kabbarah
Publicat 2019Artigo -
17
Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial per John H. Strickler, Tyler Zemla, Fang‐Shu Ou, Andrea Cercek, Christina Wu, Fabiola A. Sánchez, Joleen M. Hubbard, Brandy L. Jaszewski, Lorelei A. Bandel, Brock L. Schweitzer, Donna Niedzwiecki, Nancy E. Kemeny, Patrick M. Boland, Kimmie Ng, Tanios Bekaii‐Saab
Publicat 2019Artigo -
18
Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer per Niharika B. Mettu, Fang‐Shu Ou, Tyler Zemla, Þorvarður R. Hálfdánarson, Heinz‐Josef Lenz, Rimini Breakstone, Patrick M. Boland, Oxana Crysler, Christina Wu, Andrew B. Nixon, Emily Bolch, Donna Niedzwiecki, Alicia Elsing, Herbert I. Hurwitz, Marwan Fakih, Tanios Bekaii‐Saab
Publicat 2022Artigo -
19
Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes per Deepak L. Bhatt, Eric D. Peterson, Robert A. Harrington, Fang‐Shu Ou, Christopher P. Cannon, C. Michael Gibson, Neal S. Kleiman, Ralph G. Brindis, W. Frank Peacock, S. Brener, Venu Menon, Sidney C. Smith, Charles V. Pollack, W. Brian Gibler, E. Magnus Ohman, M. T. Roe
Publicat 2009Artigo -
20
Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient–Level Analysis of Multiple Randomized Tri... per Qian Shi, Norbert Schmitz, Fang‐Shu Ou, Jesse G. Dixon, David Cunningham, Michael Pfreundschuh, John F. Seymour, Ulrich Jaeger, Thomas M. Habermann, Corinne Haïoun, Hervé Tilly, Hervé Ghesquières, Francesco Merli, Marita Ziepert, Raoul Herbrecht, Jocelyne Flament, Tommy Fu, Bertrand Coiffier, Christopher R. Flowers
Publicat 2018Artigo
Eines de cerca:
Matèries relacionades
Medicine
Internal medicine
Cancer
Oncology
Colorectal cancer
Confidence interval
Clinical trial
Myocardial infarction
Clinical endpoint
Hazard ratio
Surgery
Cardiology
Biology
Chemotherapy
Percutaneous coronary intervention
Proportional hazards model
Gastroenterology
Oxaliplatin
Randomized controlled trial
Acute coronary syndrome
Bevacizumab
Computer science
Emergency medicine
FOLFOX
Odds ratio
Paleontology
Physical therapy
Physics
Capecitabine
Cetuximab